Stay updated on TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial

Sign up to get notified when there's something new on the TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T06:32:19.000Z thumbnail image
  6. Check
    19 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.
    Difference
    0.1%
    Check dated 2024-07-02T14:07:06.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the version of the content on the webpage.
    Difference
    0.1%
    Check dated 2024-06-27T10:18:23.000Z thumbnail image
  8. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the web page.
    Difference
    0.1%
    Check dated 2024-06-26T09:21:16.000Z thumbnail image
  9. Check
    26 days ago
    Change Detected
    Summary
    The value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less MedlinePlus Genetics related topics: Melanoma MedlinePlus related topics: Melanoma Genetic and Rare Diseases Information Center resources: Neuroendocrine Tumor Neuroepithelioma Drug Information available for: Interferon Nivolumab FDA Drug and Device Resources'. This change reflects an update in the information provided on the webpage.
    Difference
    65%
    Check dated 2024-06-25T08:38:04.000Z thumbnail image
  10. Check
    30 days ago
    Change Detected
    Summary
    The recent change to revision v2.9.0 in the webpage represents an update to the study protocol for the ACTME trial, focusing on adoptive TIL therapy with low-dose IFN-alpha plus anti-PD1 in metastatic melanoma. The change includes details on the phase I/II study protocol, safety, and efficacy assessment for patients with metastatic melanoma refractory to standard care treatments.
    Difference
    9%
    Check dated 2024-06-21T04:13:26.000Z thumbnail image

Stay in the know with updates to TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial page.